Nakano Manabu, Shimizu Eiju, Wakabayashi Hiroyuki, Yamauchi Koji, Abe Fumiaki
Food Ingredients & Technology Institute, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama, Kanagawa, 252-8583, Japan.
Shimizu Dental Clinic, 1066 Kamikobanamachi, Takasaki, 370-0077, Japan.
BMC Oral Health. 2016 Mar 22;16:37. doi: 10.1186/s12903-016-0199-7.
The main components of oral malodor have been identified as volatile sulfur compounds (VSCs) including hydrogen sulfide (H2S) and methyl mercaptan (CH3SH). VSCs also play an important role in the progression of periodontal disease. The aim of the present study was to assess the effects of the single ingestion of a tablet containing 20 mg of lactoferrin, 2.6 mg of lactoperoxidase, and 2.6 mg of glucose oxidase on VSCs in the mouth.
Subjects with VSCs greater than the olfactory threshold in their mouth air ingested a test or placebo tablet in two crossover phases. The concentrations of VSCs were monitored at baseline and 10 and 30 min after ingestion of the tablets using portable gas chromatography.
Thirty-nine subjects were included in the efficacy analysis based on a full analysis set (FAS). The concentrations of total VSCs and H2S at 10 min were significantly lower in the test group than in the placebo group (-0.246 log ng/10 ml [95 % CI -0.395 to -0.098], P = 0.002; -0.349 log ng/10 ml; 95 % CI -0.506 to -0.192; P < 0.001, respectively). In the subgroup analysis, a significant difference in the concentration of total VSCs between the groups was also observed when subjects were fractionated by sex (male or female) and age (20-55 or 56-65 years). The reducing effect on total VSCs positively correlated with the probing pocket depth (P = 0.035).
These results suggest that the ingestion of a tablet containing lactoferrin, lactoperoxidase, and glucose oxidase has suppressive effects on oral malodor.
This trial was registered with the University Hospital Medical Information Network Clinical Trial Registry (number: UMIN000015140 , date of registration: 16/09/2014).
口腔异味的主要成分已被确定为挥发性硫化物(VSCs),包括硫化氢(H2S)和甲硫醇(CH3SH)。VSCs在牙周疾病的进展中也起着重要作用。本研究的目的是评估单次摄入含有20毫克乳铁蛋白、2.6毫克乳过氧化物酶和2.6毫克葡萄糖氧化酶的片剂对口腔中VSCs的影响。
口腔空气中VSCs高于嗅觉阈值的受试者在两个交叉阶段摄入测试片或安慰剂片。使用便携式气相色谱法在基线以及摄入片剂后10分钟和30分钟监测VSCs的浓度。
基于全分析集(FAS),39名受试者纳入疗效分析。测试组在10分钟时的总VSCs和H2S浓度显著低于安慰剂组(分别为-0.246 log ng/10 ml [95% CI -0.395至-0.098],P = 0.002;-0.349 log ng/10 ml;95% CI -0.506至-0.192;P < 0.001)。在亚组分析中,当按性别(男性或女性)和年龄(20 - 55岁或56 - 65岁)对受试者进行分类时,两组之间总VSCs浓度也存在显著差异。对总VSCs的降低作用与探诊深度呈正相关(P = 0.035)。
这些结果表明,摄入含有乳铁蛋白、乳过氧化物酶和葡萄糖氧化酶的片剂对口腔异味有抑制作用。
本试验在大学医院医学信息网络临床试验注册中心注册(编号:UMIN000015140,注册日期:2014年9月16日)。